DENVER: cliexaAI – Opioid Use Disorder (OUD) Solution, is now a qualified solution on Mayo Clinic Platform, marking a major milestone in the company’s eight-year journey to build responsible, explainable, and clinically validated artificial intelligence for healthcare.

cliexaAI – Opioid Use Disorder (OUD) Solution is a containerized, production-ready clinical decision support model designed to enable early identification of patients at risk for developing opioid use disorder (OUD). The model combines an XGBoost classifier trained on real patient records with a proprietary Clinical Rules Engine (CRE) to deliver real-time, interpretable, four-tier risk stratification (Minimal, Low, Medium, or High).

Developed through participation in Mayo Clinic Platform_Accelerate, the solution integrates directly into clinical workflows and provides actionable, transparent insights to support evidence-based decision-making before addiction develops.

“This milestone validates years of investment in building explainable AI grounded in true clinical reasoning,” said Mehmet Kazgan, CEO and Founder of cliexa. “Our cliexaAI – Opioid Use Disorder (OUD) Solution has been designed to think like a clinician, anchored in medical knowledge, validated with real-world data, and built responsibly to enhance care quality, safety, and operational performance.”

Mayo Clinic Platform_Solutions Studio accelerates the development and deployment of digital health solutions by offering access to global, federated de-identified data and scalable integration into clinical workflows. The program evaluates a solution’s claims and supporting documentation to provide transparent insight into intended use, proposed value, and clinical and algorithmic performance, building credibility and supporting the adoption of transformative health technologies.

“Working with Mayo Clinic Platform speeds up digital healthcare innovation. It gives digital health companies the tools, data, and capabilities they need to more efficiently and effectively develop and deploy AI and data-centric solutions. When a solution is qualified, providers can trust it has been reviewed for adherence to responsible AI principles, all aimed at supporting care teams and improving patient outcomes,” says Steve Bethke, Vice President Solution Developer Market at Mayo Clinic Platform.

cliexa was among the first companies selected for the Mayo Clinic Platform_Accelerate program in 2022, supporting the development of clinically validated AI models across multiple specialties. Earlier collaborations include:

• Cardiovascular Care: A co-development and investment partnership with the American College of Cardiology to launch an innovative health monitoring platform for cardiovascular conditions.
• Chronic Pain and Mental Health: Peer-reviewed publication on the application of machine learning to emotional body maps for pain evaluation in partnership with University of Colorado Neuroscience Department, The Radiological Society of North America
The Psychophysiologic Disorders Society.
• Resiliency Risk Identification for Adolescents: NIH-funded collaboration with the University of Northern Colorado to develop a digital screening intervention tool for adolescent and young adult behavioral health.

cliexaAI has also been deployed for clinical applications in triage, chronic kidney disease and eating disorders with ongoing expansion into additional therapeutic areas.

About cliexa

cliexa is an AI-powered clinical intelligence platform that transforms fragmented clinical and claims data into actionable, payer-aligned insights directly within EMRs. With over 12 million real patient data points, peer-reviewed algorithms, and partnerships with leading medical institutions, cliexa empowers healthcare organizations to improve outcomes, streamline workflows, and maximize reimbursements through responsible, explainable, and compliant AI.

Mayo Clinic does not endorse or warrant the third-party products or services made available through Mayo Clinic Platform, including their functionality, quality, or performance. Mayo Clinic expressly disclaims any express or implied warranties on such third-party products or services, including any implied warranties of merchantability, quality, accuracy, fitness for a particular purpose, or noninfringement. All use of these third-party products or services, including applicable rights or remedies, are governed by separate terms with the applicable third-party developers or providers.

Fonte: Business Wire